Omega-3 lowers risk of death from heart disease 36%, new study indicates

6 November 2006

Consuming omega-3 as part of a balanced diet lowers the risk of death from heart disease by over a third, according to a new study published in the October issue of the Journal of the American Medical Association. Researchers based at Harvard School of Public Health, USA, also suggest eating fish oils, such as cod liver oil, reduces total mortality by 17%. Sarah Jarvis, chairman of the International Cod Liver Omega-3 Foundation (which is backed by an educational grant from Seven Seas, Haliborange and Pulse Fish Oil, said: "this important study provides clear and conclusive scientific proof that omega-3 significantly reduces the risk of death from heart disease."

She added: "the study also suggests, however, that consumers continue to be confused about the importance of eating oily fish, as a result of exaggerated risks made about the safety of fish. This is why ICLOF recently highlighted cod liver oil supplements as one of the safest and most effective deliverers of the best form of omega-3."

The new paper is the latest in a raft of international scientific evidence which dates back nearly 30 years and demonstrates the value of the marine-sourced omega-3 nutrients for heart health protection.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight